Valiant Organics Q3 FY26 Results: Revenue ₹5,210 Mn, EBITDA ₹616 Mn, PAT ₹175 Mn
Valiant Organics Limited reported Q3 FY26 consolidated revenue of ₹5,210 million and EBITDA of ₹616 million. For the nine-month period, revenue was ₹5,210 million, with EBITDA at ₹616 million, up 84.4% YoY. PAT for 9M FY26 was ₹175 million, a turnaround from a loss in 9M FY25. The company also noted a gross profit margin expansion to 43% for 9M FY26.
The announcement provides detailed financial results for the quarter and nine months, including revenue, EBITDA, and PAT figures. While the results show improvement, the impact is considered medium as it is a routine financial disclosure and does not involve major strategic shifts or immediate market-moving events.
The company reported positive financial results for the nine-month period of FY26, showing significant year-on-year growth in EBITDA and a turnaround in PAT from a loss to a profit. The expansion in gross profit margin and improved cost efficiencies also contribute to a positive sentiment.
Valiant Organics Limited has released its investor presentation for the third quarter and nine-month period of FY 2025-26, detailing its financial and operational performance.
For the third quarter of FY26, the company reported operational revenue of ₹5,210 million and an operating EBITDA margin of 11.82%, with operating EBITDA at ₹616 million. Profit After Tax (PAT) stood at ₹175 million, resulting in an EPS of ₹6.25 per share and a PAT margin of 3.36%. The standalone Q3 FY26 results showed a revenue of ₹1,591 million, EBITDA of ₹156 million, and PAT of ₹61 million, with an EPS of ₹2.16.
The nine-month period of FY26 saw operational revenue of ₹5,210 million, a significant increase in EBITDA to ₹616 million (up 84.4% YoY) with an improved EBITDA margin of 11.82%. PAT for the nine months was ₹175 million, a strong turnaround from a loss in the previous year's corresponding period. The standalone nine-month performance also reflected growth, with EBITDA at ₹616 million and PAT at ₹192 million.
The company highlighted that gross profit margin expanded by over 500 basis points year-on-year to 43% for the nine-month period, indicating stronger pricing discipline and improved cost efficiencies. An exceptional income of ₹57 million from an insurance claim refund positively impacted the Profit Before Tax for the period. Despite pricing pressures and demand softness in the third quarter, the cumulative nine-month performance demonstrates significant improvement in overall profitability and financial resilience.
What to do with a filing like this
Valiant Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Organics Limited. Read the original for the full detail.